Accelerate alumni



Acute Myeloid Leukemia (AML) is an aggressive blood cancer with over 60,000 new cases in developed countries each year. Up to 70% survive the first onset of the disease but these patients require long term monitoring to detect possible relapse of the disease. Current methods for monitoring the disease and detecting relapse are costly and time-consuming.

nSense is proposing a new diagnostic tool that is cheaper, more accessible and much faster than the conventional test. Our test is a ‘lab-on-a-chip’ which can detect previously validated biomarkers in cancer cells. We envisage that the chip could be easily modified to detect different blood cancers apart from AML. The design of the nSense chip also allows for the enrichment of blood cell types for further analysis.

This test could be used in hospital oncology departments, by GPs and in clinical trials to assess the efficacy of new therapeutics. We aim to partner with cancer charities and biopharmaceutical companies to deliver our test.